30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Vascular cognitive impairment and dementia (VCID) encompasses a heterogeneous group of disorders in which cerebrovascular pathology contributes to cognitive decline. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The purpose of this narrative review is to examine women's cognitive health and to highlight its association with four major pillars: (1) aging, (2) estrogen decline and loss, (3) diet, and (4) neuroinflammation, and their contribution to cognitive decline, with a focus on this combination to increase awareness and address the progression and potential amelioration of Alzheimer's disease (AD). 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hippocampal pan-histone H3 crotonylation (H3Kcr) and H3K18cr were significantly upregulated in both 5xFAD and Aβ42-injected mice compared to controls. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obesity and its associated metabolic disturbances increase the risk of cognitive decline, dementia, and anxiety-related disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Mediterranean diet, rich in plant-based foods, olive oil, and fish, has been consistently associated with slower cognitive decline and reduced risk of neurodegeneration in observational studies and some clinical trials. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
AWVs were associated with reduced risks for falls (HR: 0.976 for 2 AWVs; 0.936 for ≥3 AWVs) and fractures (HR: 0.978 for 1 AWV; 0.960 for 2 AWVs; 0.927 for ≥3 AWVs), with greater reductions observed with more AVWs. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Misconceptions were common: 38% of participants equated ACP exclusively with decisions to forgo active treatment, and many conflated ACP with current rather than future-oriented care planning. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ACP is linked to lower EOL spending and a shift from inpatient to outpatient ADRD care; structured ACP delivery should be considered. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Individual biomarkers significantly predict decline across multiple cognitive domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma Aβ levels and regional WMH burden are associated with glymphatic dysfunction as indicated by reduced ALPS. 3 key findings →
Participants: 216 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From 1990 to 2021, global ADOD burden increased markedly in absolute terms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Concurrent diarrhea and wasting (DW) among children aged 6–24 months represents a critical public health threat in East Africa, exacerbating infection susceptibility, stunting, cognitive impairment, and mortality. 2 key findings →
Participants: 1,402 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Apoptosis, a programmed cell death process activated in Alzheimer disease (AD), is not limited to neurons but extends to all cell types within the central nervous system (CNS). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
LIUS was safe and demonstrated both cognitive improvement and reduced amyloid deposition in early‐stage AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. 5 key findings →
Participants: 379 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In older adults, temporal [18F]PI-2620 binding was higher in women (β = 0.543, P < 0.001) and APOE4 carriers (β = 0.395, P = 0.030) and was positively associated with plasma p-tau217 (β = 0.22, P = 0.008). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identity-by-descent (IBD) mapping provides complementary signals to genome-wide association studies (GWASs) when multiple causal haplotypes or variants are present but not directly tested. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We developed a serum Raman spectroscopy-based ensemble learning approach for graded cognitive screening. 5 key findings →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a slow-growing neurological disorder that destroys human thought and consciousness. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 3.26 years, 321 participants converted to AD. 5 key findings →
Participants: 762 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.049, respectively), followed by musculoskeletal pain in the back and lower limbs. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Denmark is experiencing unprecedented population ageing, highlighting the importance of understanding age-related diseases, including dementia. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
SCD participants were older, had fewer years of education, more depressive symptoms, and more subjective cognitive complaints than CU participants. 4 key findings →
Participants: 315 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The development of non-pharmacological treatment approaches is supported by evidence that addressing key modifiable risk factors may prevent or delay up to 45% of dementia cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events